All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the 1st NCRI AML academy meeting, the AML Global Portal was pleased to film the headline debate on recently licensed drugs versus recent advances in transplantation. The motion for this debate was 'Advances in diagnostics and new therapies reduce the need for allogeneic transplant in AML'.
The chair for this session was Dr Steve Knapper, Cardiff University School of Medicine, Cardiff, UK. Those proponents for the motion were Dr Mike Dennis, The Christie NHS Foundation Trust, Manchester, UK and Dr David Taussig, The Royal Marsden NHS Foundation Trust, London, UK. The opposition included; Dr Rachel Protheroe, University Hospitals Bristol NHS Foundation Trust, Bristol, UK and Dr Amit Patel, University of Liverpool, Liverpool, UK. The argument for centres around the lack of survival advantage particularly in high-risk groups, whereas the argument against focuses on how new therapeutic advances could be combined with transplant to improve patient outcomes.
Debate | Advances in diagnostics and new therapies reduce the need for allogeneic transplant in AML
1st NCRI AML academy meeting | Can the new treatments for AML reduce the need for allo-HSCT?
At the 1st NCRI AML academy meeting, we spoke to Dr Mike Dennis about how new treatments for acute myeloid leukemia (AML) may reduce the need for allo-HSCT
ASH 2018 | Venetoclax in combination with chemotherapy in elderly patients with acute myeloid leukemia – CAVEAT study
Venetoclax up to 600mg in combination with 5+2 induction chemotherapy is tolerable and is associated with a high CR/CRi in patients...
Subscribe to get the best content related to AML delivered to your inbox